UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

Latest from UCSF Helen Diller Family Comprehensive Cancer Center

Novel Agents Rouse Responses in Relapsed/Refractory Multiple Myeloma

September 16, 2020

Article

Thomas G. Martin, MD, discusses the importance of targeted therapy in multiple myeloma, in addition to ongoing research.

Improved Induction Therapies Could Eliminate the Need for Transplant in Myeloma

September 16, 2020

Article

Jeffrey Wolf, MD, discusses how induction therapies continue to improve the depth of response in patients with multiple myeloma and how it may be possible to eliminate the need for autologous stem cell transplant in this population.

CTLA-4/PD-L1 Blockade Boosts Response in HCC

September 15, 2020

Article

The combination of tremelimumab and durvalumab improved overall response rate and median overall survival in patients with unresectable hepatocellular carcinoma previously treated with sorafenib.

Dr. Arora on the Evolving Treatment Landscape in Multiple Myeloma

September 11, 2020

Video

Shagun Arora, MD, discusses the rapidly advancing multiple myeloma treatment landscape.

Dr. Wong on Recent Developments in AL Amyloidosis

September 10, 2020

Video

Sandy Wong, MD, highlights recent developments in light chain amyloidosis.

Dr. Shah on Early Benefit of Orvacabtagene Autoleucel in Relapsed/Refractory Myeloma

September 03, 2020

Video

Nina Shah, MD, discusses the phase 1/2 EVOLVE study with orvacabtagene autoleucel in relapsed/refractory multiple myeloma.